Tobira aims to price IPO of 4,615,385 shares at $12.00 to $14.00

Proceeds to fund drug development, working capital, corporate purposes

By Devika Patel

Knoxville, Tenn., July 21 – Tobira Therapeutics, Inc. will sell 4,615,385 common shares in its initial public offering with a 30-day greenshoe of 692,307 additional shares, according to a Form S-1/A filed Monday with the Securities and Exchange Commission. The deal was announced June 23.

The shares will be sold at a price expected to fall between $12.00 and $14.00 per share.

BMO Capital Markets Corp., JMP Securities LLC and Oppenheimer & Co. are the joint bookrunners, and Nomura Securities International, Inc. is the co-manager.

Proceeds will be used for drug development, working capital and general corporate purposes.

The South San Francisco-based clinical-stage biopharmaceutical company intends to list its common stock on the Nasdaq Global Market under the symbol “TBRA.”

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.